Table 1. Relationship between TREX2 expression and clinicopathological features of HNSCC patients.
| HNSCC Characteristic | N | Loss of TREX2 expression n (%) | P | Stromal TREX2 expression n (%) | P |
|---|---|---|---|---|---|
| pT classification | |||||
| T1-T2 | 41 | 28 (68) | 0.719# | 12 (29) | 0.251# |
| T3 | 47 | 35 (74) | 7 (15) | ||
| T4 | 45 | 34 (76) | 9 (20) | ||
| pN classification | |||||
| N0 | 44 | 26 (59) | 0.014& | 14 (32) | 0.042& |
| N1-3 | 89 | 71 (80) | 14 (16) | ||
| Disease stage | |||||
| I-II | 19 | 10 (53) | 0.048& | 8 (42) | 0.029& |
| III-IV | 114 | 87 (76) | 20 (18) | ||
| Pathological grade | |||||
| Well-differentiated | 38 | 28 (74) | 0.323# | 8 (21) | 0.207# |
| Moderately Differentiated | 59 | 46 (78) | 9 (15) | ||
| Poorly Differentiated | 36 | 23 (64) | 11 (31) | ||
| Site | |||||
| Pharynx | 65 | 51 (78) | 0.177& | 12 (18) | 0.528& |
| Larynx | 68 | 46 (68) | 16 (24) |
Number and percentage of tumors showing either a loss of TREX2 expression in the squamous epithelia or gain of TREX2 expression in the tumor-associated stroma, with statistical evaluation.
#
Chi-square and
&
Fisher's exact tests.